Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997
Choreoathetotic Movements:A Possible Side Effect of Gabapentin
Neurol 46:851-852, Buetefisch,C.M.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Tardive Dyskinesia Associated with Use of Metoclopramide in a Child
J Pediatr 121:983-985, Putnam,P.E.,et al, 1992
Involuntary Movement & Bacterial Meningitis
Editorial, Lancet 1:142-1431987., , 1987
Unusual Neurotoxicity Associated with Amiodarone Therapy
Arch Int Med 147:881-884, Palakurthy,P.R.,et al, 1987
Extrapyramidal Reactions with Metoclopramide
BMJ 291:930-932, Bateman,D.N.,et al, 1985
Phenobarbital-Induced Dyskinesia in a Neurologically Impaired Child
Neurol 34:1600-1601, Wiznitzer,M.,et al, 1984
Anticonvulsant-induced Dyskinesias:A Comparison with Dyskinesias Induced by Neuroleptics
JNNP 39:1210, Chadwick,D.,et al, 1976